The rs9909659G/A polymorphisms of the STAT3 gene provide prognostic information in acute myeloid leukemia
The rs9909659G/A polymorphisms of the STAT3 gene provide prognostic information in acute myeloid leukemia
复制标题
STAT3基因的rs9909659G/A多态性提供急性髓系白血病的预后信息
DOI：
10.21037/tcr.2016.07.01
复制
发表时间：
2016
影响因子：
0.9
通讯作者：
Ouyang Jian
中科院分区：
文献类型：
--
作者：
Xu Peipei;Wang Xiaoyue;Xu Yong;Chen Bing;Ouyang Jian
背景：信号转导子和转录激活子3（STAT 3）是肿瘤和白血病最重要的预测因子之一。本研究旨在探讨STAT 3基因多态性与急性髓细胞白血病（AML）治疗结局的关系。方法：对152例急性髓细胞白血病（AML）患者进行疗效评价。对STAT 3基因的两个单核苷酸多态性（rs 9909659 G/A和rs 17886724 T/C）进行基因分型。使用MassARRAY系统（Sequenom）通过基质辅助激光解吸电离飞行时间质谱法进行SNP基因分型。
结果如下：结果表明，rs 17886724位点TC/CC基因型在不良组中的频率高于T/T基因型（P=0.004）。同时，rs 17886724中的C等位基因更频繁地被归类为不利组（P=0.023）。不同rs 9909659基因型的年龄和性别分类相似。M7、低血红蛋白、不利的细胞遗传学因素、不利的基因突变因素和高乳酸脱氢酶（LDH）与rs 9909659的GA/AA基因型相关（分别为P=0.031、P= 0.000、P = 0.000、P=0.019和P=0.001）。rs 9909659基因型为GA/AA的患者治疗效果较差，包括细胞遗传学不良和疗效差（分别为P=0.001和P=0.038）。显然，具有rs 9909659的GA/AA基因型的AML患者对标准化疗不敏感。
结论：STAT 3基因rs 9909659 G/A多态性可用于预测AML患者的治疗结局。
Background: The signal transducer and activator of transcription 3 (STAT3) is one of the most prominent predictable factors for cancer and leukemia. This study aimed to investigate the relationship between STAT3 gene polymorphisms and the treatment outcome of acute myelogenous leukemia (AML) in a Chinese population. Methods: A total of 152 AML patients were included in our study, and the therapeutic effects were evaluated. Two single nucleotide polymorphisms (SNPs) in the STAT3 gene (rs9909659G/A and rs17886724T/C) were genotyped. SNP genotyping was performed using the MassARRAY system (Sequenom) via matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
Results: The results illustrated that the frequency of the TC/CC genotype of rs17886724 was higher in the unfavorable group than that of the T/T genotypes (P=0.004). Meanwhile, the C allele in rs17886724 was more frequently classified into the unfavorable group (P=0.023). Age and gender classifications were similar for different rs9909659 genotypes. Patients with M7, low hemoglobin, unfavorable cytogenetic factor, unfavorable gene mutation factor, and high lactate dehydrogenase (LDH) were associated with the GA/AA genotype in rs9909659 (P=0.031, P=0.000, P=0.000, P=0.019, and P=0.001, respectively). Patients with the GA/AA genotype of rs9909659 suffered from poor treatment, including unfavorable cytogenetic and poor response (P=0.001 and P=0.038, respectively). Clearly, AML patients with the GA/AA genotype of rs9909659 were not sensitive to standard chemotherapy.
Conclusions: The rs9909659G/A polymorphisms of the STAT3 gene could be used to predict the treatment outcome in AML patients.